Brief: Summit Therapeutics Q1 Net Income USD -62.9 Million
01/05/2025 21:09
May 01 (Reuters) - Summit Therapeutics Q1 operating expenses USD 66.8 million. Q1 EPS USD -0.09
Recent news on Summit Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Intel, Victoria's Secret, Super Micro
U.S. STOCKS ON THE MOVE-Novo Nordisk, Intel, Oracle
Summit Therapeutics rebounds after pulling stock offering
Brief: Summit Therapeutics Withdraws Proposed Underwritten Public Offering Effective- SEC Filing
Summit Therapeutics falls on launching $500 mln stock offering